Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza, Human Infections Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who meet the study population criteria

Exclusion criteria

Subjects with a history of hypersensitivity to the ingredients of zanamivir

Treatment and study plan

Zanamivir hydrate

Drug

Primary outcomes

The number of incidence of adverse events in subjects treated with zanamivir

Time frame: 11 days
Occurrence of influenza virus infection

Time frame: 11 days

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start: 2007
Primary completion: 2009
Study completion: 2009
First posted: Jul 11, 2011
Registry last updated: May 16, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed